AI Article Synopsis
- Metachromatic leukodystrophy (MLD) is an autosomal recessive disorder caused by a deficiency in arylsulfatase A, leading to accumulation of cerebroside sulfate and subsequent demyelination.
- Clinical symptoms differ with age: late-infantile has rapid progression, juvenile shows slower decline, and adult-onset may present with psychiatric issues.
- Diagnosis involves enzyme testing, imaging, and other criteria, and while there's no cure for MLD, management focuses on supportive care and potential treatments like hematopoietic stem cell transplantation.
Article Abstract
This abstract provides an overview of metachromatic leukodystrophy (MLD), an autosomal recessive disorder stemming from arylsulfatase A deficiency. MLD leads to cerebroside sulfate accumulation, causing central and peripheral demyelination. Clinical manifestations vary by age group: late-infantile (rapid progression), juvenile (slower progression), and adult-onset (psychiatric symptoms). A case study details a 23-year-old with progressive vision impairment, motor weakness, and cognitive changes. Examination and MRI findings led to suspicion of MLD, later confirmed by enzyme testing. Optic nerve involvement is emphasized, along with diagnostic criteria involving enzyme assays, imaging, and urinary sulfatide excretion tests. While no cure exists, symptomatic and supportive care, including hematopoietic stem cell transplantation, remains key in MLD management
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511329 | PMC |
| http://dx.doi.org/10.1016/j.radcr.2023.08.087 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!